Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a Korean company to achieve blockbuster status, the biotech company said Wednesday ...
Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it the first product in Korean biopharmaceutical history to exceed the 1 ...
The efficacy and safety of Remsima (subcutaneous) compared with Remsima (intravenous) in people with Crohn's disease and ulcerative colitis was assessed in an unpublished open-label randomised, phase ...
Celltrion's autoimmune disease treatment Remsima (ingredient infliximab) topped 1 trillion won in annual sales again this year. Celltrion said on the 10th that Remsima posted about 1.0495 trillion won ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...
INCHEON, South Korea — Celltrion, Inc. (KRX:068270) today announced that the company has completed Phase 3 clinical trial for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, the autoimmune ...
Celltrion Healthcare, Korean biosimilar giant Celltrion’s sales unit, announced that the company has won the Brazilian Federal Government’s bid to supply biosimilar infliximab Remsima for the third ...
Celltrion said on the 11th that it has launched the liquid formulation of its autoimmune disease treatment Remsima (ingredient name Infliximab) in Europe. According to Celltrion, the company recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results